<DOC>
	<DOCNO>NCT00017173</DOCNO>
	<brief_summary>RATIONALE : Inserting p53 gene person 's cancer cell may improve body 's ability fight cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy p53 gene may kill tumor cell . PURPOSE : Phase II trial study effectiveness gene therapy plus surgery follow cisplatin radiation therapy treat patient newly diagnose resectable stage III stage IV cancer mouth throat .</brief_summary>
	<brief_title>S0011 , Gene Therapy &amp; Surgery Followed Chemo &amp; RT Newly Diagnosed Cancer Mouth Throat</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility treat patient newly diagnose resectable stage III IV squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx surgery Ad5CMV-p53 gene follow cisplatin radiotherapy . - Determine progression-free survival , local control , overall survival patient treat regimen . - Determine toxicity regimen patient population . OUTLINE : This multicenter study . Patients undergo surgical resection receive intraoperative Ad5CMV-p53 gene injection resection bed deep soft tissue bed cervical level nodal metastasis . Patients also receive third intraoperative Ad5CMV-p53 gene injection neck dissection bed , allow sit place 10 minute . Within 48-72 hour surgery , patient receive postoperative Ad5CMV-p53 gene injection two drainage catheter next mucosal suture line neck dissection bed , allow sit place 2 hour . Within 56 day surgery , patient receive cisplatin IV 30-90 minute day 1 , 22 , 43 radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Patients may receive 3 additional day radiotherapy high-risk area day 43-45 . Patients follow every 2-6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 60 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm highrisk/limited stage III IV squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx Newly diagnose Previously untreated Considered surgically resectable Evidence regional lymph node metastasis ( N1N3 ) No distant metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN Hepatitis B surface antigen negative Hepatitis C antibody negative Renal : Creatinine great 2 time ULN Creatinine clearance least 60 mL/min Other : Magnesium normal ( magnesium supplement allow ) No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission HIV negative Not pregnant nursing Patients must use effective barrier contraception prevent bodily fluid transmission 28 day Ad5CMVp53 gene administration PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No concurrent intensitymodulated radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
</DOC>